key: cord-0291173-9vhp4oy2
authors: Carey, Ryan M.; Hariri, Benjamin M.; Adappa, Nithin D.; Palmer, James N.; Lee, Robert J.
title: HSP90 function is required for T2R bitter taste receptor nitric oxide production and innate immune responses in human airway epithelial cells and macrophages
date: 2021-11-19
journal: bioRxiv
DOI: 10.1101/2021.11.16.468387
sha: 29473881ebf543b2aaeb087f23180baf2195c6ea
doc_id: 291173
cord_uid: 9vhp4oy2

Bitter taste receptors (T2Rs) are G protein-coupled receptors (GPCRs) expressed in various cell types including ciliated airway epithelial cells and macrophages. T2Rs in these two airway innate immune cell types are activated by bitter products, including those secreted by common airway pathogens like Pseudomonas aeruginosa, leading to Ca2+-dependent activation of endothelial nitric oxide (NO) synthase (eNOS). NO production leads to enhanced mucociliary clearance and direct antibacterial effects by ciliated epithelial cells as well as increased phagocytosis by macrophages. Using biochemistry and live cell imaging, we explored the role of heat shock protein 90 (HSP90) in regulating T2R-dependent NO pathways in primary sinonasal epithelial cells, primary monocyte-derived macrophages, and a human bronchiolar cell line (H441). We used immunofluorescence to show that H441 cells express eNOS and certain T2Rs and that the bitterant denatonium benzoate activates NO production in an HSP90-dependent manner in cells grown either as submerged cultures and at air liquid interface. In primary sinonasal epithelial cells, we determined that HSP-90 inhibition reduces T2R-stimulated NO production and ciliary beating which are crucial for pathogen clearance. In primary monocyte-derived macrophages, we found that HSP-90 is integral to T2R-stimulated NO production and phagocytosis of FITC-labeled Escherichia coli and pHrodo-Staphylococcus aureus. Our study demonstrates that HSP90 serves an innate immune role by regulating NO production downstream of T2R signaling by augmenting eNOS activation without impairing upstream calcium signaling. These findings suggest that HSP90 plays an important role in airway antibacterial innate immunity and may be an important target in airway diseases like chronic rhinosinusitis, asthma, or cystic fibrosis.

Bitter taste receptors (also known as taste family 2 receptors, or T2Rs, encoded by TAS2R genes) are G protein-coupled receptors (GPCRs) used by the tongue to detect bitter compounds (1, 2) . However, many of the 25 human T2R isoforms are also expressed in other organs (1) (2) (3) (4) (5) , including the nose, sinuses, and lungs (6, 7) . These receptors regulate diverse processes like airway smooth muscle contraction (8) (9) (10) (11) and innate immune responses in the oral epithelium (12). T2R receptors are also expressed in immune cells like monocytes and macrophages (13) (14) (15) , which are important players in airway innate immunity (16, 17) . In the airway epithelium, T2R isoforms 4, 14, 16, 38, and possibly others are expressed in bronchial and nasal motile cilia (18-21). These T2Rs are activated in response to acyl-homoserine lactone (AHL) and quinolone quorum-sensing molecules secreted by the common airway pathogen Pseudomonas aeruginosa (18, 22, 23) .

Activation of the T2Rs in sinonasal cilia or unprimed (M0) macrophages causes Ca 2+dependent activation of nitric oxide (NO) synthase (NOS) (4, 18, (24) (25) (26) (27) (28) , likely the endothelial NOS (eNOS) isoform expressed in both airway ciliated cells (29-32) and M0 macrophages (33).

In ciliated cells, NO activates soluble guanylyl cyclase to produce cyclic GMP (cGMP). NO activates protein kinase G (PKG) to elevate ciliary frequency to increase mucociliary clearance, the major physical defense of the airway. The T2R-activated NO also directly diffuses into the airway surface liquid (ASL), where it can have antibacterial effects (18, 34) . NO can damage bacterial cell walls and/or DNA (35, 36) . NO can also inhibit the replication of many respiratory viruses, including influenza, parainfluenza, rhinovirus,(37) and SARS-CoV-1 & -2 (38-41). In macrophages, T2R-stimulated NO production and cGMP production acutely increases phagocytosis (42). Thus, T2R to NO signaling may also be an important therapeutic target in infectious diseases beyond the airway. As NOS and NO have been implicated in chronic rhinosinusitis (43) as well as asthma and other lung diseases (44), better understanding of the mechanisms of NOS activation in airway epithelial cells may have implications beyond T2Rs.

The importance of T2Rs in upper airway defense is supported by observations that patients homozygous for the AVI TAS2R38 polymorphism, which renders the T2R38 receptor non-functional, have increased frequency of gram-negative bacterial infection (18), have higher levels of sinonasal bacteria in general (45, 46) and specifically have higher levels of biofilmforming bacteria (47), have higher frequency of chronic rhinosinusitis (48-51), and exhibit worse outcomes after functional endoscopic sinus surgery (52). One study has suggested that TAS2R38 genetics may also play a role in cystic fibrosis P. aeruginosa infection (53), though other studies have suggested that TAS2R38 may not be a modifier gene in CF (54, 55).

Recently, an association between the TAS2R38 PAV (functional) genotype has been associated with a lower mortality of SARS-COV2 compared with the AVI (non-functional) genotype (56).

Better understanding the role of T2R38 and other T2Rs in airway innate immunity is important for determining if and how to leverage these receptors as therapeutic targets or predictive biomarkers.

In this study, we explored the role of heat shock protein 90 (HSP90) in T2R function in two types of cells important for airway innate immunity: ciliated epithelial cells and macrophages. The members of the HSP90 class of molecular chaperones are highly conserved and ubiquitously expressed (57). In addition to promoting protein folding, HSP90 regulates signaling by facilitating trafficking or localization of signaling proteins and/or functioning as molecular scaffolds to bring signaling molecules together. Because HSP90 is critical for endothelial cell NO production via eNOS, we tested if HSP90 is involved in T2Rdependent NO generation. HSP90 proteins can facilitate eNOS activation via scaffolding of eNOS with activating kinases such as Akt or Ca 2+ -bound calmodulin (CaM) kinases (58-62).

HSP90 has been localized to the base of airway cell cilia (63-65), suggesting HSP90 may be localized close to T2Rs in airway ciliated cells and may help facilitate their signal transduction to eNOS. Recently, it was proposed that HSP90 inhibition by geldanamycin can revert Th2-and Th17-induced airway epithelial goblet cell metaplasia (66) . If HSP90 inhibition reduces T2R NO responses, this may have unwanted effects of reducing T2R/NO-mediated innate immunity.

To test the requirement for HSP90 in T2R signaling, we combined biochemistry and live cell imaging with a human bronchiolar cell line, primary sinonasal epithelial cells, and primary monocyte-derived macrophages. Results below reveal important molecular insights into the T2R signaling pathway in both airway epithelial and immune cells and identify a specific role for HSP90 in airway epithelial NO-mediated innate immunity.

HEK293T cells were obtained from ATCC and cultured in high glucose DMEM (ThermoFisher Scientific) plus 10% FetalPlex serum substitute and 1x cell culture Pen/Strep. For transfection, cells were seeded onto 8 well chambered glass coverslips (pre-coated with poly-D-lysine) and transfected with eNOS-RFP, Wt HSP90, and/or D88N HSP90 (Kindly provided by W. Sessa, Addgene plasmids # 22497, #22487, and/or #22480, respectively). S119A eNOS-RFP was generated by site directed mutagenesis from Wt eNOS-RFP and verified by sequencing (University of Pennsylvania Penn Genomic Analysis Core DNA Sequencing Facility). Cells were stimulated with 10 µg/ml SC79 that was made from 10mg/ml SC79 stock in DMSO. Control solutions had 0.1% DMSO as vehicle control. No effects of DMSO alone were observed. RFP fluorescence was used to verify similar transfection efficiencies in all experiments.

Essential Media (MEM) with Earle's salts plus 10% FetalPlex serum substitute and 1x cell culture Pen/Strep. Cells were seeded and imaged on plastic 48 well plates as they stuck very poorly to glass. For air-liquid interface (ALI) cultures, H441 cells were seeded onto collagencoated 1.1 cm 2 transwell filters (for intracellular DAF-FM) or 0.33 cm2 transwell filters (for extracellular Daf-2; 0.4 µm pore size, transparent; Corning) and grown to confluence for 5 days before exposing the apical side to air, as described previously for 16HBE and Calu-3 cells (20, 67) . H441 ALIs were switched to Lonza bronchial epithelial cell basal media (BEBM) plus Singlequot supplements (differentiation media) upon confluence and exposure to air. When culture medium was removed from the upper compartment, basolateral media was changed to differentiation medium (1:1 DMEM:BEBM) containing hEGF (0.5 ng/ ml), epinephrine (5 ng/ml), BPE (0.13 mg/ml), hydrocortisone (0.5 ng/ml), insulin (5 ng/ml), triiodothyronine (6.5 ng/ml), and transferrin (0.5 ng/ml), supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 0.1 nM retinoic acid, and 2% NuSerum (BD Biosciences, San Jose, CA) as described (18). Cells were fed from the basolateral side only with differentiation media for ~21 days before use.

Submerged H441 cells were infected with Green GENIe-expressing BacMam (Montana Molecular, Bozeman, MT) as per the manufacture's protocol for adherent cells; media was changed 4-6 hours after infection to BacMam-free media containing 2 mM NaButyrate to maintain expression. For siRNA, H441s were treated with Acell SMARTPool siRNAs (Horizon Discovery, Waterbeach, UK) for human eNOS (NOS3; Catalog ID:E-006490-00-0005), nNOS (NOS1; Catalog ID:E-009496-00-0005), PAR-2 (Catalog ID:E-005095-00-0005), or non-targeting pool (Catalog ID:D-001910-10-05) as per the manufacturer's instructions and as previously described (42). H441 cells were transfected with Wt or D88N HSP90 (Kindly provided by W. Sessa, Addgene plasmids #22487 or #22480, respectively) using Lipofectamine 3000 and the specific H441 protocol provided on the ThermoFisher Scientific website. We used 5 µL of lipofectamine and 2 µg DNA per 8-well chambered coverglass (CellVis), equating to 0.25 µg DNA/well, with each well approximately equivalent to a 48 well plate in surface area. Primary human M0 macrophages were cultured as previously described (68) in high glucose RPMI2650 media with 10% human serum and 1x cell culture Pen/Strep. De-identified monocytes from healthy apheresis donors were obtained from the University of Pennsylvania Human Immunology core, and macrophages were differentiated by adherence culture for 12 days in 8-well chamber slides (CellVis) as described (68) . Our prior studies suggest no differences in T2R responses among macrophages differentiated by adherence alone or by adherence plus M-CSF (42), and thus adherence only was used for these studies. within one month of surgery. Individuals ≤18 years of age, pregnant women, and cognitively impaired persons were not included. Tissue was transported to the lab in saline on ice and mucosal tissue was immediately removed for cell isolation.

Sinonasal epithelial cells were enzymatically dissociated and grown to confluence in proliferation medium (DMEM/Ham's F-12 plus BEBM) for 7 days (18-20, 69). Confluent cells were dissociated and seeded on Corning transwells coated with BSA, type I bovine collagen, and fibronectin. When culture medium was removed from the upper compartment, basolateral media was changed to differentiation medium as described above. Primary ALI cultures were genotyped for TAS2R38 PAV or AVI polymorphims (70, 71) as described (18-20).

Adherent, submerged HEK293Ts in 20 mM HEPES-buffered Hank's Balanced Salt solution (HBSS) were simultaneously loaded and stimulated for 30 min in the presence of 10 µM DAF-FM-diacetate (DA) ± SC79 as indicated. HEK293Ts were then immediately washed three times in HBSS and imaged as below. Submerged H441 cells were loaded for 30 minutes with 10 µM DAF-FM-DA or fura-2 acetoxymethyl ester (AM) (ThermoFisher Scientific) in 20 mM HEPES-buffered HBSS supplemented with 1x MEM amino acids followed by washing with HBSS + 1x MEM amino acids. Calbryte 590 AM (AAT Bioquest) was loaded similarly. When used, L-NAME (10 µM), D-NAME (10 µM), U73122 (1 µM), U73343 (1 µM), or geldanamycin (all from Cayman Chemical) were included in the loading solution as 30 min pretreatment; cPTIO (10 µM) was only added after loading. Cells were then washed out of DAF-FM into HBSS with the continued presence of inhibitor for the start of the experiment. Transwells were loaded with DAF-FM for 60 min and placed into a glass-bottom 12 well dish (CellVis) prior to imaging.

Macrophages were loaded with 5 µM fura-2-AM or DAF-FM DA for 45 min as previously described (68 

Whole-field CBF was measured using the Sisson-Ammons Video Analysis system (73) as previously described (18, 74, 75) (74) (75) (76) (77) , changes in CBF were normalized to baseline CBF. This was validated by measurements of raw baseline CBF (in Hz) between control and experimental cultures, as indicated in the text.

IF was carried out as previously described (18) (19) (20) . ALI cultures were fixed in 4% formaldehyde for 20 min at room temperature, followed by blocking and permeabilization in phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA), 5% normal donkey serum (NDS), 0.2% saponin, and 0.3% triton X-100 for 1 hour at 4°C. A549 or 16HBE cells were fixed in 4% formaldehyde for 20 min at room temp, followed by blocking and permeabilization in PBS containing 1% BSA, 5% NDS, 0.2% saponin, and 0.1% triton X-100 for 30 min at 4°C. Primary antibody incubation (1:100 for anti-T2R antibodies, 1:250 for tubulin antibodies) were carried out at 4°C overnight. Incubation with AlexaFluor (AF)-labeled donkey anti-mouse and rabbit secondary antibody incubation (1:1000) was carried out for 2 hours at 4°C. Transwell filters were removed from the plastic mounting ring and mounted with Fluoroshield with DAPI (Abcam; Cambridge, MA USA)). For co-staining of T2R14 and T2R38, Zenon antibody labeling kits (Thermo Fisher Scientific) were used to directly label primary antibodies with either AF546 or AF647 as described (18) (19) (20) . Images of ALIs were taken on an Olympus Fluoview confocal system with IX-73 microscope and 60x (1.4 NA) objective and analyzed in FIJI (78) . Images of submerged H441 cells were taken on an Olympus IX-83 microscope with 60x (1.4 NA) objective using Metamorph. Anti-T2R38 (ab130503; rabbit polyclonal) and anti-beta-tubulin IV (ab11315; mouse monoclonal) antibodies were from Abcam.

Anti-T2R14 (PA5-39710; rabbit polyclonal) primary antibody and conjugated secondary antibodies (donkey anti-rabbit AlexaFluor 546 and donkey anti-mouse AlexaFluor 488) were from Thermo Fisher Scientific. Alpha-tubulin antibody was from Developmental Studies Hybridoma Bank (12G10; mouse monoclonal; University of Iowa, Iowa City). Anti-eNOS antibody (NB-300-605; rabbit polyclonal) was from Novus (Littleton, CO). Immunofluorescence images were analyzed in FIJI (78) using only linear adjustments (min and max), set equally between images that are compared. Compared images were always taken with the same exposure, objective, and other camera and microscope settings. Both conventional (0 = black) and inverted (0 = white) lookup tables (LUTs) were used in this study to illustrate localizations as clearly as possible. Inverted LUTs were from ChrisLUTs FIJI package (https://github.com/cleterrier/ChrisLUTs; C. Leterrier, Neuropathophysiology Institute, Marseille University).

Phagocytosis assay were carried out as descried (68) . Macrophages were incubated with heat-killed FITC-labeled Escherichia coli at 250 µg/ml (strain K-12; reagents from Vybrant phagocytosis assay kit; ThermoFisher Scientific; Cat # E2861) in phenol red-free, low glucose DMEM ± denatonium benzoate or other agonists or inhibitors for 15 min at 37°C. As we found that phagocytosis was negligible from temperatures of 4 °C up to room temp in these assays Phagocytosis assays were also carried out similarly using 125 µg/ml pHrodo red-labeled S. aureus (strain Wood 46; ThermoFisher Scientific, cat # A10010) (68) . As pHrodo dyes only fluoresce when particles are internalized into low pH endosomes (previously demonstrated in (42)), this assay does not require washing or quenching of the extracellular pHrodo S. aureus.

Macrophages were incubated with pHrodo-S. aureus for 30 min at 37°C as described (68) with excitation at 555 nm and emission at 595 nm measured on the Tecan Spark 10M plate reader.

Background measurements were made using wells containing fluorescent S. aureus in the absence of macrophages. Representative images were taken as above except using a standard TRITC filter set (Semrock).

Multiple comparisons were made with one-way ANOVA with Bonferroni (pre-selected pairwise comparisons), Tukey-Kramer (comparing all values), or Dunnett's (comparing to control value) post-tests; p <0.05 was considered statistically significant. Asterisks (* and **) indicate p <0.05 and p <0.01, respectively. All data in bar graphs are shown as mean ± SEM. Image data were analyzed in FIJI (78) and numerical data were analyzed in Excel (Microsoft) and/or Prism (GraphPad software, La Jolla, CA).

To first determine if we could recapitulate results that HSP90 is important for eNOS function (62, 79-82) in a reductionist model, we expressed eNOS-RFP in HEK293Ts, an eNOS null cell line (83) . We measured NO production using reactive nitrogen species (RNS)-sensitive dye DAF-FM over 30 min. One mechanism by which eNOS can be activated is phosphorylation at S1177 (S1179 in bovine eNOS). We found that expression of S1179D eNOS dramatically increased DAF-FM fluorescence compared with Wt eNOS-RFP or S1179A eNOS-RFP ( Figure   1A -B). DAF-FM fluorescence increases likely reflected NO production as they were inhibited after 30 min pre-treatment and in the continued presence of 10 µM L-NAME but not inactive control D-NAME ( Figure 1B) . We also observed that HSP90 inhibitor geldanamycin (10 µM; 30 min pre-treatment then continued throughout the 30 min experiment) also reduced DAF-FM fluorescence in S1179D eNOS-RFP-expressing cells. Supporting that the effects of geldanamycin were mediated by HSP90 inhibition, we also found that co-transfection of a dominant negative (DN) HSP90 isoform (D88N) (82) reduced DAF-FM fluorescence while Wt HSP90 did not significantly change DAF-FM fluorescence ( Figure 1B) .

Small molecule Akt activator SC79 also induces eNOS phosphorylation and NO production in airway epithelial cells (84). We found that SC79 (10 µg/ml) activates DAF-FM fluorescence increases in HEK293Ts transfected with Wt eNOS but not untransfected cells ( Figure 1C) . In Wt eNOS-transfected cells, SC79-induced DAF-FM fluorescence increases were reduced by Akt inhibitor MK2206 or GSK690693 (10 µM; 30 min pre-treatment then continued throughout the 30 min experiment) as well as co-transfection with dominant negative (K179M) Akt (85) (Figure 1D ). SC79-induced DAF-FM fluorescence increases were also blocked by HSP90 inhibitors geldanamycin or BIIB 021 ( Figure 1D ). Further supporting the role of HSP90 in eNOS function, we found that co-transfection of DN HSP90 in SC79-stimulated HEK293Ts reduced DAF-FM fluorescence ( Figure 1E ). All together, these data suggest that HSP90 is important for eNOS-mediated NO production.

When we transfected GFP-tagged eNOS (86) and mCherry-tagged HSP90 (87) into submerged A549 airway cells, chosen here because of their transfectability and their ability to stick well to glass. We saw punctate perinuclear localization of eNOS likely reflecting Golgi, as eNOS localizes partly to the Golgi in endothelial cells (83) (Figure 1F ). We also saw some likely plasma membrane eNOS localization at cell-cell contact points (Figure 1F) , also expected from studies of endothelial cells (86) . HSP90 localization was more global (Figure 1F) , though perinuclear puncta were observed. However, when we exited GFP and collected mCherry emission, we saw an mCherry emission signal that almost identically overlapped with GFP-eNOS localization ( Figure 1F ). As GFP and mCherry are a donor-acceptor pair for Förster resonance energy transfer (FRET), we hypothesized that we were collecting emission from mCherry-HSP90 in close proximity to the excited GFP-eNOS. When this experiment was performed with GFP-eNOS and mCherry alone (no HSP90), no mCherry emission was detected with GFP excitation (Figure 1F ). A549 cells endogenously express T2R bitter taste receptors activated by the bitter agonist denatonium benzoate (88) . When we monitored GFP and mCherry emission, both with GFP excitation, we noted an increase in mCherry emission and concomitant decrease in GFP emission with denatonium benzoate stimulation ( Figure 1G ), suggesting that an increase in FRET occurs with bitter agonist stimulation. This increase in FRET was not observed during stimulation with Na benzoate and was reduced with HSP90 inhibitor geldanamycin ( Figure 1H ). Together, these A549 data suggest that heterologouslyexpressed HSP90 and eNOS are partly closely co-localized in an airway cell line, and this association or close co-localization may increase during T2R stimulation.

We next wanted to test if HSP90 activity affects endogenous eNOS function when activated by endogenous T2R receptors. We started by examining if T2R stimulation activates We also noted positive T2R4 and T2R46 immunofluorescence in submerged H441s ( Figure 2D -F). T2R4 staining was highly similar to the pattern observed for plasma membrane glucose transporter Glut1 (Figure 2E ), while T2R46 appeared to be more diffusely localized but also possibly localized to the edges of H441 cell islands ( Figure 2F ). Like many GPCRs, a substantial amount of T2R46 immunofluorescence was located intracellularly, possibly representing ER and/or trafficking compartments. However, potential plasma membrane staining was observed at the cell periphery. The implications for these different staining patterns are unclear, but our goal here was to test for T2R expression and not perform detailed localization analysis. The rationale for examining T2R4 and 46 was that T2R4 localizes to nasal cilia (19, 20) and T2R46 localizes to bronchial cilia (5) . Both are also expressed in human monocyte-derived macrophages (42). Immunofluorescence appears to support that both T2R4 and T2R46 are also expressed in H441s in addition to downstream eNOS. Quantitative PCR (qPCR) of submerged H441s for the T2Rs responsive to denatonium benzoate also suggested expression of both T2R4 and T2R46, as well as T2R30 (formerly known as T2R47) and possibly T2R13 and T2R10 ( Figure 3A ).

All of these T2Rs (4, 46, 10, 13, and 30) are activated by the bitter compound denatonium benzoate, which activates eight out of 25 human T2R isoforms (93, 94). The denatonium benzoate effective concentrations for T2R4 and T2R46 are 300 and 30 µM, respectively, with an EC50 of ~240 µM reported for T2R46 in heterologous HEK293T expression systems. To test if denatonium benzoate activated NO production in submerged H441s, we loaded these cells with reactive nitrogen species-sensitive dye DAF-FM to track NO production, as done previously in primary nasal cells (19, 20) . Stimulation of DAF-FM-loaded H441s with 1 mM denatonium benzoate caused an increase in intracellular DAF-FM fluorescence ( Figure 3B ). The S-nitrosothiol NO donor SNAP (20 µM) was used in these experiments as a positive control. Denatonium-induced DAF-FM responses were also inhibited by NO scavenger carboxy-PTIO (cPTIO; 10 µM added at the beginning of the experiment; Figure 3C ) or after 45 min pre-treatment with 10 µM NOS inhibitor L-NAME but not inactive D-NAME ( Figure 3C) . Furthermore, H441 DAF-FM responses to denatonium benzoate were inhibited by eNOS but not nNOS or scramble siRNA ( Figure 3D ). This supports that the DAF-FM responses measured reflect eNOS-mediated NO production. We also observed that HSP90-induced DAF-FM increases were reduced in cells transfected with a dominant negative HSP90 beta (D88N-HSP90; Figure 3F ). D88N-HSP90 blocks VEGF-induced NO production in endothelial cells (82) . Transfection of Wt HSP90 had no effect on the denatonium response ( Figure 3F ). We also saw reduction of NO responses with D88N-HSP90 during stimulation with T2R agonists quinine (500 µM) and thujone (1 mM) ( Figure 3F ), which activate T2Rs in bronchial (5) and nasal cilia (95). Quinine activates 11 T2Rs including T2R4 and 46, while Thujone activates T2Rs 14 and 10 (94, 96). These results suggest that T2R agonist-stimulated NO responses require HSP90 function in H441 cells. We also saw that denatonium-induced DAF-FM fluorescence increases were also reduced ≥50% by pretreatment (1 hour) with 10 µM HSP-90 inhibitor geldanamycin ( Figure 3G) , suggesting denatonium-induced (likely T2R-induced) NO production requires HSP90 activity. There was no alteration of the denatonium-induced Ca 2+ response with this concentration of geldanamycin ( Figure 3H) , suggesting the role of HSP90 is likely downstream of the Ca 2+ signaling. NO increases intracellular cGMP by activating soluble guanylyl cyclase. We tested if denatonium stimulation increased cGMP using a cGMP fluorescent biosensor (Green GENie;

Montana Molecular). Denatonium caused an increase in cGMP (decrease in Green GENIe F/Fo; plotted inversely in Figure 4A -B) that was likewise inhibited by blockade of NOS activity by L-NAME ( Figure 4A and C) or geldanamycin pretreatment (Figure 4B and C) . These results all suggest that full activation of eNOS and downstream cGMP production during T2R agonist stimulation in H441 cells requires HSP90 function.

We grew H441 cell monolayers at ALI, a more physiological cell culture model for airway epithelial cells than submerged cells. H441 ALIs have been used to study ion transport and other epithelial parameters (97) (98) (99) (100) (101) . Denatonium benzoate, but not sodium benzoate, activated NO production in H441 ALIs, measured by intracellular DAF-FM fluorescence ( Figure   5A -B). While sodium benzoate does activate some T2Rs, it activates a subset (T2R14 and T2R16) distinct from denatonium benzoate with much lower affinity (94) . Thus, we use sodium benzoate as a control here for osmotic effects and potential pH effects due to permeation of the benzoate moiety. Denatonium-induced DAF-FM fluorescence increases were completely blocked by Ca 2+ chelation by intracellular BAPTA-loading (45 min, 10 µM) plus 0-Ca 2+ extracellular buffer (containing 2 mM EGTA to chelate trace calcium; Figure 5C ). This suggests a requirement for Ca 2+ signaling. Like submerged cells, the DAF-FM response was also reduced by 45 min pre-treatment with HSP90 inhibitor geldanamycin (10 µM) or NOS inhibitor L-NAME (10 µM) but not HSP70 inhibitor VER-155008 (10 µM; Figure 5D ). Thus, HSP90 inhibition reduces T2R-mediated NO production in H441 ALIs.

NO is a highly diffusive gas that can rapidly diffuse across cell membranes (102) . When a small volume (100 uL) of cell impermeant NO indicator DAF-2 (10 µM) was placed on top of the H441 ALIs in the presence of denatonium benzoate or sodium benzoate for 30 min, we observed a 3-fold higher fluorescence of apical DAF-2 in denatonium-treated cultures ( Figure   6A ). This suggest that NO produced can diffuse into the airway surface liquid, as previously show in primary sinonasal ALIs (18). The denatonium-induced DAF-2 fluorescence increase was reduced by PLC inhibitor U73122 but not inactive U73343 (Figure 6A) , suggesting it depended on GPCR signaling. We found that T2R agonists denatonium benzoate and quinine, but not sodium benzoate, both increased apical DAF-2 fluorescence in a NOS-dependent manner, as responses were inhibited by L-NAME but not D-NAME ( Figure 6B) . These DAF-2 responses, likely reflecting NO diffusion into the ASL, were blocked by pretreatment (10 µM, 45 min) with GPCR G protein inhibitor YM-254890 (103) (104) (105) or HSP90 inhibitors geldanamycin, 17-AAG, or BIIB 021 ( Figure 6C ) but were not blocked by HSP70 inhibitor VER-15508. Like submerged H441s, we saw inhibition with eNOS siRNA but not with scramble, nNOS, or PAR-2 siRNA ( Figure 6D) .

We examined NO production using DAF-FM in primary sinonasal cells grown from residual surgical material and differentiated at ALI as described (18, 19, 69 ). These cells express T2R receptors in apical motile cilia ( Figure 7A and (18-21) ). Note that, unlike H441 assays, denatonium benzoate was not used in primary nasal cell assays. While primary bronchial ciliated cells respond to denatonium benzoate (5), we find that nasal ciliated cells do not (18, 26), likely due to differential T2R expression between bronchial and nasal cells. For primary nasal cells, we instead used the T2R38-specific agonist phenylthiocarbamide (PTC) (70, 71) in primary ALIs genotyped for functional (PAV) or non-functional (AVI) polymorphisms in TAS2R38 encoding the T2R38 receptor (18, 71, 106) . Homozygous PAV/PAV TAS2R38 cells produced NO in response to 1 mM PTC while AVI/AVI cells did not ( Figure 7B ). The NO produced during PTC stimulation was inhibited by geldanamycin (10 µM, 45 min pre-treatment; Figure 7C ). We also tested quercetin, another plant flavonoid shown to be a T2R14 agonist in heterologous expression assays (109) . While quercetin was previously shown to increase (CBF) (110) and reduce cAMP signaling (111), a mechanism for these effects was not elucidated. As T2Rs also decrease cAMP through inhibitory G protein signaling in airway cells (19, 112), we hypothesized that quercetin may act as a T2R agonist in airway epithelial cells. Quercetin (50 µM) stimulation likewise increased DAF-FM fluorescence that was blocked by 4'-fluoro-6-methoxyflavanone or geldanamycin ( Figure 7D ). Apigenin and quercetin-stimulated DAF-FM fluorescence responses are summarized in Figure 7E .

We also performed similar assays as in H441s in Figure 5 to measure NO diffusion into the ASL using 30 µL of DAF-2 solution overlaid onto the primary nasal ALIs. Both PTC (1 mM) and P. aeruginosa quorum-sensing molecule 3oxoC12HSL (100 µM) increased apical surface DAF-2 fluorescence in a manner that was T2R38 dependent as it occurred in PAV/PAV (functional T2R38 homozygous) cultures but not AVI/AVI (non-functional T2R38 homozygous) cultures ( Figure 7F) . PTC-and 3oxoC12HSL-induced increases in DAF-2 fluorescence were inhibited by geldanamycin, 17-AAG, or BIIB 021 but not VER-15008 (all 10 µM for 45 min pretreatment; Figure 7F ). Apigenin (100 µM) increased apical DAF-2 fluorescence in a manner that was inhibited by T2R14 antagonist 4'-fluoro-6-methoxyflavanone (108) (50 µM for 45 min pre-treatment; Figure 7G ) or PLC inhibitor U73122 (10 µM for 45 min pre-treatment; Figure   7G ). Apigenin-stimulated DAF-2 increases were also reduced by HSP90 inhibitors geldanamycin or 17-AAG but not by HSP70 inhibitor VER 155008 (all 10 µM for 45 min pretreatment) (Figure 7G ). Phospholipase C (PLC) inhibitor U73122 (10 µM for 45 min pretreatment) also inhibited the apigenin response while inactive analogue U74434 had no effect.

As a control, when apigenin or vehicle was incubated in DAF-2 solution in the absence of cells (just transwells), no differences in DAF-2 fluorescence were observed ( Figure 7G ). Figure 7 suggest that HSP90 function is required for NO production during T2R38 or T2R14 activation in primary nasal epithelial cells. We tested if this affected ciliary beat frequency (CBF) using the T2R14 agonist apigenin. As previously described (20), apigenin increased ciliary beat frequency ~10-15% over 10 min. This was blocked by T2R14 antagonist 4'-fluoro-6-methoxyfavanone or HSP90 inhibitors geldanamycin or BIIB 021 (10 minute pretreatment, 10 µM) but not by HSP70 inhibitor VER 1555008 (Figure 8A-B) . Thus, HSP90

inhibitors reduced apigenin-stimulated T2R14 CBF responses. We also observed a ~30% increase in CBF with apical application of 25 µM quercetin ( Figure 8C ) that was reduced by the T2R14 inhibitor 4'-fluoro-6-methoxyflavanone (108) or geldanamycin. There was no inhibition of CBF increases in response to purinergic agonist ATP (50 µM; Figure 8A and C). Quercetinstimulated increases in CBF were also inhibited by blocking NO signaling with L-NAME (10 µM; Figure 8D ). These data suggest quercetin activation of CBF may occur through T2R activation and NO production. Importantly, we observed that geldanamycin has no significant effect on baseline CBF after ≥20 min (Figure 8E ), in contrast to prior studies in mouse tracheal cells, where geldanamycin rapidly reduced CBF to ~75% of basal values, postulated to be due to reduced stability of tubulin polymerization upon HSP90 inhibition (65).

We wanted to examine T2R signaling to eNOS in another human primary cell model to test if it requires HSP90 function. Like epithelial cells, macrophages are important players in early innate immunity. Unprimed (M0) monocyte-derived macrophages also express eNOS involved in enhancement of phagocytosis during immune receptor activation (33). While isolated monocytes differentiate into Mfs that are not exactly the same as alveolar Mfs that populate the airways at baseline (113) (114) (115) , monocyte-derived Mfs are often used as surrogates for alveolar Mfs and are nonetheless themselves important for infections, including during chronic airway inflammation like CRS, chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis (17, 116, 117) . We previously observed that T2R stimulation in human M0 monocyte-derived macrophages also activates low-level Ca 2+ responses that drive NO production to enhance phagocytosis (68) . Macrophage DAF-FM responses to denatonium benzoate were significantly reduced by HSP90 inhibitors geldanamycin and BIIB 021 (10 µM; 30 min pre-treatment; Figure 9A ) despite no change in denatonium-induced Ca 2+ signals ( Figure   9B ), suggesting that HSP90 is required for activation of eNOS and/or nNOS downstream of the T2R-induced Ca 2+ response (68).

We measured phagocytosis of FITC-labeled Escherichia coli ( Figure 9C ). First, we had to test effects of geldanamycin alone. It was previously shown that geldanamycin treatment and HSP90 inhibition increases phagocytosis after ~90 minutes due to transcriptional up-regulation of HSP70 (118, 119) . We observed an increase in baseline phagocytosis after ~2 hours geldanamycin treatment ( Figure 9D) ; this was inhibited by HSP70 inhibitor VER-155008 ( Figure 9D ), supporting these prior observations. Thus, to avoid any effects of HSP70 upregulation, we tested the effects of geldanamycin on denatonium-upregulated phagocytosis after only 30 min geldanamycin pretreatment followed by continued geldanamycin treatment for the 15 minutes of the phagocytosis assay (45 min total). We observed a ~3 fold increase in phagocytosis in response to 1 mM denatonium benzoate (as we previously reported (42)) that was inhibited by geldanamycin as well as pertussis toxin (Figure 9E) , which inactivates the Gi and Ggustducin Ga subunits that can couple to T2R receptors (112, 120, 121) . We also saw inhibition of denatonium benzoate-induced or quinine (500 µM)-induced phagocytosis of pHrodo-labeled S. aureus with geldanamycin pretreatment (Figure 9F) . Together, these data suggest that HSP90 plays a key role in activation of NO production downstream of T2R activation.

To confirm that our FITC-E. coli measurements reflected phagocytosis and to test a pathogen with more relevance to the airway epithelium, we also tested pHrodo-labeled Staphylococcus aureus, as previously utilized in (42). The pHrodo dye fluorescence strongly in acidic environments and thus exhibits a marked increase in fluorescence when internalized into acidic organelles like lysosomes and phagosomes. Assays were carried out similarly to FITC-E. coli assays described above. We observed that denatonium benzoate (1 mM) increased phagocytosis in a NOS-dependent manner as it was inhibited by L-NAME but not D-NAME (10 µM, 30 min pre-treatment; Figure 10A-B) . The increased phagocytosis in response to denatonium benzoate or P. aeruginosa 3oxoC12HSL (100 µM) was inhibited by geldanamycin or BIIB 021 (10 µM pretreatment; Figure 10C-D) , supporting reduction of this innate immune response by HSP90 inhibitors. We tested other HSP90 inhibitors using pHrodo S. aureus in the same assay in a plate reader format (as described in the methods and (42)). Well fluorescence increased when macrophages were incubated with 1 mM denatonium benzoate for 15 min ( Figure 10E ). Equimolar sodium benzoate had no effect (Figure 10E) . The stimulatory effect of denatonium benzoate was reduced by pertussis toxin (to block T2R GPCR signaling) or preincubation (15 min; 10 µM) with geldanamycin, BIIB 021, or 17-AAG but not VER 155008 ( Figure 10E ).

HSP90 likely plays a multi-faceted role in airway epithelial physiology beyond facilitating protein folding, but data surrounding its specific contributions are unclear. There has been an increasing interest in heat shock chaperone proteins in immune cell modulation (122) , including regulation of immune cell metabolism (123) and immune receptor signaling (124, 125) . Here, we show a new innate immune role for HSP90, namely the production of NO downstream of T2R signaling. Specifically, we show that HSP90 inhibition by multiple structurally diverse compounds acutely impairs NO-mediated airway epithelial CBF responses and macrophage phagocytosis without impairing the upstream calcium signaling. Thus, the result of HSP90 inhibition is not simply impaired receptor function, trafficking, or folding. The defect appears to specifically affect eNOS activation and not Ca 2+ signaling. We utilized several models, including heterologous expression in HEK293T and A549 cells as well as primary cells differentiated from patient material.

The T2R to eNOS pathway, specifically polymorphisms regulating T2R38 signaling, has been identified as clinically important in terms of increased susceptibility to upper respiratory infections and impaired patient outcomes in chronic rhinosinusitis (CRS) (45-48, 50-52, [126] [127] [128] . T2R signaling to eNOS regulates both airway ciliary beating and macrophage phagocytosis. Others have shown that HSP90 is important for scaffolding eNOS with activating proteins like Akt or Ca 2+ -bound calmodulin. We hypothesize that this scaffolding function is likewise important for T2R activation of eNOS. This puts HSP90 in a prime role to regulate eNOS output during T2R stimulation. HSP90 transcript levels can be regulated by a host of transcription factors active during inflammation or cell stress, including HSF1, NF-IL6, and NFkB (129) . Various posttranscriptional modifications, from phosphorylation to nitrosylation (129, 130) , can also alter HSP90 activity. We hypothesize that regulation of HSP90 may be one way to modulate airway T2R/eNOS NO output or airway NO output in general. In a myocardial ischemia-reperfusion injury mouse model, transfection of HSP90 is protective by enhancing eNOS S1177 (activating site) phosphorylation and decreasing eNOS T495 (inhibitory site) phosphorylation (131) . We hypothesize that HSP90 expression might be a pathway that could be exploited to increase NO in airway diseases associated with reduced NO levels, including CF (132) (133) (134) (135) (136) (137) (138) (139) (140) or primary ciliary dyskinesia (141) (142) (143) .

While HSP90 has been shown to be important for baseline cilia function (63-65), other studies have suggested it is necessary for Th2 (IL-13-driven) and Th17 (IL-17-driven) airway goblet cell metaplasia (66) . Many airway diseases, including asthma, COPD, and CF, are characterized by a loss of ciliated cells due to goblet or squamous metaplasia, likely impairing mucociliary clearance both through mucin hypersecretion and loss of cilia (144) . HSP90

inhibition was suggested to be potentially useful in type 2 inflammatory airway disease characterized by airway remodeling, typically goblet cell metaplasia (66) , which include asthma and chronic rhinosinusitis. However, outside the airway, HSP90 has been implicated in both pro-inflammatory and anti-inflammatory processes (122) . A better understanding is needed of how HSP90 contributes to the myriad of functions that airway epithelial cells perform, including bacterial surveillance and antimicrobial responses.

While HSP90 is required for NO production during stimulation of airway and macrophage T2R s, the inhibition of HSP90 did not affect T2R-mediated Ca 2+ signals upstream of the NO production. HSP90 inhibition did reduce cGMP production, elevation of ciliary beating, and phagocytosis, all downstream of NO production. Thus, HSP90 inhibition may reduce innate immune responses to bacteria in the airway, through both epithelial cells and dedicated immune cells. The overall effect on airway innate immunity will depend on other pathways that are up or down regulated. It may be that the reversal of goblet metaplasia in asthma with HSP90 inhibition outweighs a side-effect of reduced T2R responses, but the knowledge that these T2R responses are reduced may suggest other supplemental targets/therapies are needed to boost NO production in patients receiving HSP90 inhibitors. Here, we simply show one effect of HSP90 inhibition that would be predicted to be detrimental. Other effects of HSP90 inhibitors in the airway must be studied in more detail to clarify the entire picture of how these drugs may affect the respiratory epithelium and innate defense.

As described above, HSP90 has been localized to the base of airway cilia (63, 64) in close proximity to eNOS (29, 32, 64, 145) and T2Rs (5, (18) (19) (20) . We found that T2R activation produces more NO in ciliated airway cells than stimulation of purinergic receptors (18) or PAR-2 (69), despite the fact that these other GPCRs generate higher Ca 2+ responses than T2Rs. A clearer picture of the T2R signaling pathway is necessary to understand why this occurs. It may be that the close proximity of T2Rs to eNOS and HSP90 creates localized Ca 2+ or calmodulin microdomains within the cilia. Another explanation is that other T2R-stimulated pathways downstream or in parallel to the Ca 2+ also contribute to these responses. While eNOS can be activated directly through interactions with Ca 2+ -bound calmodulin (146, 147) , it can also be activated by phosphorylation at multiple residues by kinases like Akt, CaMKII, or PKA (148) (149) (150) (151) (152) (153) (154) (155) (156) (157) . Phosphorylation at one or more eNOS residues may be important during T2R activation of NO production. While much work on T2Rs has focused on Ca 2+ Mean baseline CBF was not with vehicle or 4'-fluoro-6-methoxyflavanone pre-treatment (7.5 ± 1.1 Hz or 8.2 ± 0.9 Hz, respectively; not significant by Students' t test). Mean baseline CBF was also not different before or after vehicle or geldanamycin pre-treatment (6.9 ± 1.7 Hz or 7.9 ± 1.2 Hz; respectively; not significant by Students' t test). B: Bar graph of mean ± SEM of CBF responses from 5 independent experiments as shown in A using ALIs from 4 different patients.

Significance determined by 1-way ANOVA with Bonferroni posttest; *p<0.05. C: Left shows representative normalized CBF responses (representative experiments shown) to T2R14/39 agonist quercetin in human ALIs ± T2R14/39 inhibitor 4'-fluoro-6-methoxyflavanone. Mean baseline CBF was not with vehicle or 4'-fluoro-6-methoxyflavanone pre-treatment (7.3 ± 1.2 Hz or 7.9 ± 0.6 Hz, respectively; not significant by Students' t test). Right shows normalized CBF responses (representative experiments shown) to quercetin ± geldanamycin (10 µM; 5 min pretreatment). Mean baseline CBF was not different before or after vehicle or geldanamycin pretreatment (7.4 ± 1.3 Hz or 7.0 ± 0.9 Hz; respectively; not significant by Students' t test). D: Bar graph of mean ± SEM of CBF responses from 5 independent experiments as shown in C using ALIs from 5 different patients. Significance determined by 1-way ANOVA with Bonferroni posttest; **p<0.01. E: Graph shows real-time measurement of CBF (mean ± SEM of 6 independent experiments using ALIs from 3 patients) during prolonged geldanamycin treatment, followed by stimulation with purinergic agonist ATP. A + D-NAME + L-NAME 

Taste perception: from the tongue to the testis

Oral and extra-oral taste perception

Taste and smell GPCRs in the lung: Evidence for a previously unrecognized widespread chemosensory system

Taste receptors in innate immunity

Motile cilia of human airway epithelia are chemosensory

Taste Receptors in Upper Airway Innate Immunity

Taste receptors in the upper airway

Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction

TAS2R activation promotes airway smooth muscle relaxation despite beta(2)-adrenergic receptor tachyphylaxis

Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity

Bitter taste receptor T2R14 detects quorum sensing molecules from cariogenic Streptococcus mutans and mediates innate immune responses in gingival epithelial cells

Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists

HSP90 inhibitor geldanamycin reverts IL-13-and IL-17-induced airway goblet cell metaplasia

Plant flavones enhance antimicrobial activity of respiratory epithelial cell secretions against Pseudomonas aeruginosa

Bitter taste receptors stimulate phagocytosis in human macrophages through calcium, nitric oxide, and cyclic-GMP signaling

Protease-activated receptor 2 activates airway apical membrane chloride permeability and increases ciliary beating

The genetics of phenylthiocarbamide perception

The molecular basis of individual differences in phenylthiocarbamide and propylthiouracil bitterness perception

Computer control of microscopes using microManager

All-digital image capture and whole-field analysis of ciliary beat frequency

Molecular modulation of airway epithelial ciliary response to sneezing

Vasoactive intestinal peptide regulates sinonasal mucociliary clearance and synergizes with histamine in stimulating sinonasal fluid secretion

In vitro studies of a distillate of rectified essential oils on sinonasal components of mucociliary clearance

Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex

Dominantnegative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells

The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway

Trafficking of endothelial nitric-oxide synthase in living cells. Quantitative evidence supporting the role of palmitoylation as a kinetic trapping mechanism limiting membrane diffusion

2-color photobleaching experiments reveal distinct intracellular dynamics of two components of the Hsp90 complex

The bitter end: T2R bitter receptor agonists elevate nuclear calcium and induce apoptosis in non-ciliated airway epithelial cells

Endothelial nitric oxide synthase is expressed in cultured human bronchiolar epithelium

Estrogen acutely stimulates endothelial nitric oxide synthase in H441 human airway epithelial cells

Transcriptional regulation of SP-B gene expression by nitric oxide in H441 lung epithelial cells

The Role of Quinine-Responsive T2Rs in Airway Immune Defense and Chronic Rhinosinusitis

BitterDB: a database of bitter compounds

Water Permeability Adjusts Resorption in Lung Epithelia to Increased Apical Surface Liquid Volumes

Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro

Amiloride-sensitive fluid resorption in NCI-H441 lung epithelia depends on an apical Cl(-) conductance

Inhibition of Na+ transport in lung epithelial cells by respiratory syncytial virus infection

Lentiviral small hairpin RNA delivery reduces apical sodium channel activity in differentiated human airway epithelial cells

Nitric oxide gas phase release in human small airway epithelial cells

A novel Galphaq/11-selective inhibitor

Functional evidence for biased inhibition of G protein signaling by YM-254890 in human coronary artery endothelial cells

Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule

Expression and Functional Activity of the Human Bitter Taste Receptor TAS2R38 in Human Placental Tissues and JEG-3 Cells

Bitter taste receptor activation by flavonoids and isoflavonoids: modeled structural requirements for activation of hTAS2R14 and hTAS2R39

6-methoxyflavanones as bitter taste receptor blockers for hTAS2R39

The bitter pill: clinical drugs that activate the human bitter taste receptor TAS2R14

Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: therapeutic implications for chronic rhinosinusitis

Distinct action of flavonoids, myricetin and quercetin, on epithelial Cl(-) secretion: useful tools as regulators of Cl(-) secretion

Coupling of Airway Smooth Muscle Bitter Taste Receptors to Intracellular Signaling and Relaxation Is via Galphai1,2,3

Macrophage heterogeneity and acute inflammation

Distinct bone marrow-derived and tissue-resident macrophage lineages proliferate at key stages during inflammation

Monocyte and macrophage heterogeneity

Human Cystic Fibrosis Macrophages Have Defective Calcium-Dependent Protein Kinase C Activation of the NADPH Oxidase, an Effect Augmented by Burkholderia cenocepacia

Cystic Fibrosis Lung Immunity: The Role of the Macrophage

Increase in phagocytosis after geldanamycin treatment or heat shock: role of heat shock proteins

Rescuing of deficient killing and phagocytic activities of macrophages derived from non-obese diabetic mice by treatment with geldanamycin or heat shock: potential clinical implications

Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways

Gustducin is a taste-cell-specific G protein closely related to the transducins

Heat Shock Proteins as Immunomodulants

A guide to immunometabolism for immunologists

The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction

Thrombin receptor signaling to cytoskeleton requires Hsp90

Single Nucleotide Polymorphisms in Chemosensory Pathway Genes GNB3, TAS2R19, and TAS2R38 Are Associated with Chronic Rhinosinusitis

Divergent bitter and sweet taste perception intensity in chronic rhinosinusitis patients

T2R38 genotype is correlated with sinonasal quality of life in homozygous DeltaF508 cystic fibrosis patients

Mechanisms of Hsp90 regulation

Post-translational modifications of Hsp90 and their contributions to chaperone regulation

Heat shock protein 90 transfection reduces ischemia-reperfusion-induced myocardial dysfunction via reciprocal endothelial NO synthase serine 1177 phosphorylation and threonine 495 dephosphorylation

Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium

Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype

Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis

Reduced exhaled NO is related to impaired nasal potential difference in patients with cystic fibrosis

Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression

Nitric oxide deficiency contributes to impairment of airway relaxation in cystic fibrosis mice

Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, Pseudomonas infection, and polyunsaturated fatty acids

Nitric oxide and L-arginine deficiency in cystic fibrosis

Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene

Nasal nitric oxide and nitric oxide synthase expression in primary ciliary dyskinesia

Primary ciliary dyskinesia: diagnostic and phenotypic features

Expression of nitric oxide synthases in primary ciliary dyskinesia

First contact: the role of respiratory cilia in host-pathogen interactions in the airways

Alcohol stimulates ciliary motility of isolated airway axonemes through a nitric oxide, cyclase, and cyclic nucleotide-dependent kinase mechanism

Nitric oxide synthases: regulation and function

Trafficking and activation of eNOS in epithelial cells

Life history of eNOS: partners and pathways

Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase

AMP-activated protein kinase phosphorylation of endothelial NO synthase

eNOS activation mediated by AMPK after stimulation of endothelial cells with histamine or thrombin is dependent on LKB1

Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer

AMP-activated protein kinase and nitric oxide regulate the glucose sensitivity of ventromedial hypothalamic glucoseinhibited neurons

Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells

Facilitation of myocardial PI3K/Akt/nNOS signaling contributes to ethanol-evoked hypotension in female rats

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase